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Abstract
Progress in systems medicine brings promise to addressing patient heterogeneity and indi-
vidualized therapies. Recently, genome-scale models of metabolism have been shown to
provide insight into the mechanistic link between drug therapies and systems-level off-tar-
get effects while being expanded to explicitly include the three-dimensional structure of pro-
teins. The integration of these molecular-level details, such as the physical, structural, and
dynamical properties of proteins, notably expands the computational description of bio-
chemical network-level properties and the possibility of understanding and predicting whole
cell phenotypes. In this study, we present a multi-scale modeling framework that describes
biological processes which range in scale from atomistic details to an entire metabolic net-
work. Using this approach, we can understand how genetic variation, which impacts the
structure and reactivity of a protein, influences both native and drug-induced metabolic
states. As a proof-of-concept, we study three enzymes (catechol-O-methyltransferase, glu-
cose-6-phosphate dehydrogenase, and glyceraldehyde-3-phosphate dehydrogenase) and
their respective genetic variants which have clinically relevant associations. Using all-atom
molecular dynamic simulations enables the sampling of long timescale conformational
dynamics of the proteins (and their mutant variants) in complex with their respective native
metabolites or drug molecules. We find that changes in a protein’s structure due to a muta-
tion influences protein binding affinity to metabolites and/or drug molecules, and inflicts
large-scale changes in metabolism.
Author Summary
Structural systems pharmacology is an emerging field of computational biology research
that aims to merge network and molecular views of biology. Genome-scale models are in
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silico, network models of metabolism, and by integrating the detailed knowledge we can
gain from molecular simulations with these models, we can begin to understand whole cell
phenotypes at a more complete scale. In this study, we use and integrate a variety of simu-
lation tools at both the network and molecular levels to allow us to understand how a
mutation can change an enzyme’s ability to bind to drugs or metabolites. We look at three
different enzymes within red blood cell metabolism, and find that these computational
tools reflect what we know about them relatively well, and also potentially serve as a work-
flow for understanding other traits in the overall theme of personalized medicine.
Introduction
Synergistic advances in pharmacogenomics, genome-wide association studies (GWAS) and
next-generation sequencing bring promise to future applications of personalized medicine.
Exploring the mechanistic link between human sequence variation and responses to drug ther-
apy is likely to shed light on why certain drugs show a reduced or even harmful effect on spe-
cific individuals. For example, if an individual has a specific polymorphism or rare variant, the
consequences of administering a given drug are potentially immense if a life-threatening gene-
drug association has not yet been identified [1]. While numerous harmful gene-drug associa-
tions have been identified from GWAS (and those with significant side effects now have warn-
ings on pharmaceutical labels [2]), screening genome-wide associations across the broad scope
of available pharmaceutical compounds is currently limited by both the cost of carrying out
such studies [3] as well as a lack of statistical power due to the rarity of deleterious mutations.
To address these limitations, a number of recent studies have developed mechanistic,
computational analyses and the construction of omics-based workflows that identify, for exam-
ple, the mode of action of common drug side effects [4]. Genome-scale modeling enables the
analysis of disease-causing mutations in mechanistic detail. Genome-scale models of metabo-
lism (GEMs) encompass the known interactions of diverse biological components, or the reac-
tome of a target organism, into a unified, functional framework. This framework contains all
known metabolic reactions, the genes that encode each enzyme, and all metabolites in a given
organism and therefore provides a direct mapping from genes, to gene products, to the pheno-
typic responses of cellular activity. Mapping sequence variations in a gene to changes in the
biological states of an entire metabolic network enables characterizing the effects of sequence
variation in simplified cellular systems, such as the human erythrocyte [5,6]. Furthermore, a
recently updated version of the erythrocyte metabolic model (iAB-RBC-283), based on the
global reconstruction of the human metabolic network (Recon 2) [7] has been used to study
the response of the cell to deleterious single nucleotide polymorphisms (SNPs) as well as drugs
with known targets [5,8,9].
Predicting the wide range of possible effects that SNPs and single nucleotide variations
(SNVs) can have on structure-function relationships in proteins requires extending a systems-
level description to include details from physics-based approaches, such as molecular dynamics
simulations. To this end, three-dimensional structures of proteins provide complementary
data for further elucidating changes in drug-protein interaction networks. Much attention has
been placed on developing bioinformatics tools for the statistical analysis of large-scale data
sets, (which contain information on non-synonymous, exonic mutations on individual pro-
teins), and generating hypotheses that explain how mutations affect stability, protein-protein
interactions, ligand binding, or catalytic function [10]. Atomistic simulations have been used
as a complement to experimental methods to assess changes in relative binding affinities of
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potential lead compounds to key enzymatic targets [11]. While these approaches are rich in
molecular-level details, they are limited in their ability to address how significant the observed
changes are in the context of an entire biochemical pathway or, ultimately, a whole cell. This
limitation thus motivates the need to develop novel workflows that integrate systems-level and
molecular-level details to characterize biological processes at graded levels of chemical detail
[12–14].
The growing field of structural systems biology brings promise to the integration of systems
and molecular sciences, enabling applications in personalized medicine [13,15–17], drug dis-
covery [18–20], understanding off target binding [21–23] or mechanisms of action, [24–26]
and also to enhance pharmacokinetic/pharmacodynamic models [27]. Here, we build upon
previous studies which integrate protein structural information into GEMs [22,23,28], by
developing a multi-scale framework to analyze the effects of sequence variation on drug
responses in human erythrocyte metabolism (Fig 1). Using genome-scale modeling
approaches, we identify key proteins in erythrocyte metabolism that are perturbed in the pres-
ence of (i) pharmaceutical drugs and (ii) sequence variants. Using atomistic simulations, we
characterize changes in structure and function relationships for different metabolic proteins in
the form of drug or metabolite binding differences resulting from reported sequence variants.
Finally, we integrate the knowledge gained from these simulations into a detailed genome-scale
model of the erythrocyte, allowing for both constraint-based and kinetic methods of analysis to
understand the systems-wide effect of these variants.
Fig 1. A novel workflow for advancing systems pharmacology. Starting from the genome-scale model of
human erythrocyte metabolism (iAB-RBC-283 [8]), we integrate information from sequence and structure
databases, such as UniProt [40] and the Protein Data Bank (PDB) [30]. Using information from the PDB,
experimental protein structures are linked to their respective encoding genes and interacting partners in the
metabolic networks. Using homology modeling, representative templates are used to build structural models of
target proteins when existing experimental structural information is sparse or missing. The resulting GEnome-
scale model of Metabolism with PROtein structures, GEM-PRO, (referred to as iNM-RBC-283-GP), presents all
of this information in a single database and can be used to generate hypotheses related to cell function in the
presence of environmental perturbations. Using other external databases such as the PharmGKB [29],
information about known SNPs, drug-related effects, and pharmacogenomic data is used to find promising
protein targets that are characterized at the molecular level. Finally, the information gained from structural
simulations (e.g. substrate docking and molecular dynamics simulations) can be used as input to guide systems
modeling and test hypotheses related to drug-induced effects on metabolism.
doi:10.1371/journal.pcbi.1005039.g001
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Results and Discussion
Pharmacogenomics in the human erythrocyte
We were interested in quantifying the number of proteins in the human erythrocyte metabo-
lism that (i) are known pharmaceutical targets and (ii) have been documented with both dis-
ease and non-disease causing mutations (Fig 2(A)). The erythrocyte presents a valuable and
tractable model system for studying the effects of human genetic variation on drug metabolism.
First, it is widely appreciated that the erythrocyte possesses drug metabolizing capabilities such
that extracts of erythrocyte enzymes are commonly used as a general measure of enzyme activ-
ity [31,32]. Second, genetic changes that occur in cells other than the erythrocyte are often
manifested in the erythrocyte, assuming correct isoforms and similar genetic control [33–36].
The ease of collection of human erythrocyte samples and subsequent purification of enzymes
of interest motivates the study of the erythrocyte as an in silicomodel that can be tested against.
Lastly, the erythrocyte outnumbers any other cell type in the human body (85% of the total cell
count) [37].
Fig 2. In a), coverage of structural and pharmacogenomics information for the human erythrocyte. The metabolic network is based on 346 proteins, and
each narrow slice of the pie chart represents one protein. The innermost circle represents structural coverage by an experimental structure (dark green) or
by a homology model (light green). The middle circle indicates if the gene is known to contain at least one disease causing SNP (dark blue), at least one
missense SNV or SNP (blue), or no recorded SNVs/SNPs (light blue). The outermost circle includes information from various drug databases, and
indicates if that protein is known to be a drug or drug metabolite target (dark orange) or if no drugs target that protein (light orange). Basic subsystems of
erythrocyte metabolism are highlighted as regions of the chart. For a full chart of numeric counts for each category and subsystem division see Fig C in S1
Text. In b), pharmacogenomics knowledge base generation. Our knowledge base includes information on: drugs or metabolites that are predicted to bind
to/are metabolized by a protein; known associations between a drug and variation within a population; all variation sites that alter the sequence of the
protein target. Targets are filtered into four classes based on if there is a protein structure available, if a SNP causes known effects on drug or metabolite
catalysis or binding, and finally if the protein itself is important within the context of the import and export of metabolites in the erythrocyte from gene
knockout simulations and flux variability analysis (FVA). Included at the bottom are examples of genes that match these classes of information.
doi:10.1371/journal.pcbi.1005039.g002
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Starting from the set of metabolic genes in the genome-scale model, iAB-RBC-283 [8], we
mapped gene identifiers to cross-referenced information from dbSNP [38], OMIM [39], and
UniProt [40]. We find that for 6800 exon coding SNPs in genes which are expressed in the
erythrocyte, the majority (>90%) are missense SNPs as opposed to frameshift or insertion/
deletion variations. These SNPs map to 247 of the 281 genes (88%) in the erythrocyte model.
The majority of these annotated as “disease-causing”map to enzymes within the heme biosyn-
thesis, glycolysis, and galactose metabolism pathways, which is consistent with hemolytic dys-
function. Other non-disease causing SNPs, (or SNPs with unknown associations), occur in
nucleotide metabolism. Harmful mutations also tend to alter the type of amino acid much
more than non-disease causing SNPs. For instance, mutations from a hydrophobic residue to
another hydrophobic residue are quite common, but disease causing SNPs greatly increase this
type of amino acid change to a polar, non-polar, or positive amino acid (Fig D in S1 Text).
Our pipeline also identifies variants that potentially influence drug-binding capabilities of
respective proteins. Of the metabolic proteins in the erythrocyte, 143 are found to be potential
targets for pharmaceutical action. We find 343 drugs (approved, experimental, withdrawn
drugs, or drug metabolites) that bind to different proteins in the model [41,42]. In addition,
mapping to the PharmGKB database, we find 274 deleterious SNP-drug associations, or docu-
mented adverse reactions (i.e., pharmaceutical complications) in patients (referred to herein as
SNP-drug association). To summarize, our systems pharmacological database provides details
on all documented missense SNPs in erythrocyte metabolism, whether they are causal for dis-
ease or cause pharmaceutical complications in a significant percentage of the human popula-
tion with a sequence variation [29]. In addition, our dataset contains information on drug-
binding capabilities of all proteins in the model. This combined source of information for
genetic and pharmacological information within the erythrocyte allows for the selection of
interesting targets to further analyze with both molecular and systems simulations.
Mapping protein structures to the metabolic network of the human
erythrocyte
To address the structural implications of changes to sequence or drug-binding capacity, we
were interested in mapping all protein-encoding genes within the metabolic network of the
erythrocyte to their three-dimensional (3D) macromolecular structures. Integration of protein
structural data and GEMs has previously been described through the construction of GEnome-
scale models of Metabolism with PROtein structures (GEM-PRO). The established pipelines
for constructing a GEM-PRO have been recently updated [28]. Applying this procedure for the
human erythrocyte metabolic model, we start from the existing GEM, iAB-RBC-283 [8], and
the final outcome is a mapping of all protein-encoding genes to the 3D structures of their cata-
lyzing enzymes. The selected protein structures have been quality-controlled and ranked to
ensure the highest quality structures are retained. The new GEM-PRO model, iNM-RBC-
283-GP, initially contained structural coverage for 181 of the 346 proteins in the metabolic net-
work (Fig 2(A)), and includes a total of 1766 unique PDB entries (the original GEM is com-
prised of 281 genes which encode 346 unique proteins). In addition, 312 homology models
were obtained for proteins from existing homology model databases [43], using the I-TASSER
suite of programs [44].
Our QC/QA pipeline identifies experimental structures and homology models that can be
used with high confidence in molecular modeling simulations [28]. Several quality metrics are
used to rank-order structures, including: (i) coverage of the wild-type amino acid sequence
(with a wild-type being defined as the canonical UniProt sequence); (ii) X-ray structure resolu-
tion; (iii) number of missing or unresolved parts of the structure. The final QC/QA statistics
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indicate that 36% of proteins in the GEMmodel (125/346) have high quality structural infor-
mation, whereas the remaining 64% (221/346 proteins) can be represented by template-based
and ab initio generated homology models (see Fig C in S1 Text for detailed statistics on subsys-
tem coverage).
Interestingly, when we combine the structural data and the pharmacogenomic data, we are
able to assess SNP data in the context of protein structural information and derive new associa-
tion. For example, we find that, on average, disease causing SNPs are 4 Å closer to annotated
enzyme active sites than non-disease causing SNPs. All structural annotations, mapped data-
base information, and quality statistics are included as a supplementary database (S1
Database).
Identifying signature proteins with disease phenotypes
One of the main advantages of assembling a structural systems pharmacological dataset for the
erythrocyte is that it can be used to address questions requiring multi-scale perspectives, such
as “Can mutating a single amino acid in a protein influence network-level perturbations, and,
ultimately lead to disease phenotypes?” Considering the availability of information (pharmaco-
genomic and structural) that emerged from our mapping efforts, we were interested in focusing
on several specific cases that could be studied in greater molecular detail, using a combined sys-
tems and molecular modeling approach.
To this end, we assessed the available experimental, pharmacogenomic, protein structural
and metabolic information available for all proteins in the erythrocyte model. Given the data
collected from publically available datasets (described above), we classified proteins based on:
(i) availability of experimental protein structure, drug or metabolite binding information, (ii)
known harmful gene-drug associations and (iii) if the knockout of this gene within the context
of erythrocyte caused significant changes in metabolite import and export (see Methods),
resulting in four different classes of proteins based on these criteria (Fig 2(B)). This categoriza-
tion mainly aids in the next steps of our contributed workflow, in studying the effects of SNVs
on metabolite and drug binding using all-atom molecular simulations.
As shown in Fig 2(B), Class I targets have the most information available, including 3D pro-
tein structures (some in complex with a metabolite, drug or analogue), known drug-protein
interactions, gene-drug associations, and clinically relevant phenotypic responses to a drug
therapy. This group of proteins includes six proteins: catechol-O-methyltransferase (COMT),
aldehyde dehydrogenase (ALDH3A1), adenosine deaminase (ADA), glucose-6-phosphate
dehydrogenase (G6PD), glutathione peroxidase 1 (GPX1), and uridine 5'-monophosphate
synthase (UMPS). Class II targets provide case-studies amenable to experimental testing SNV
or drug-induced effects. Class III & IV targets are proteins found to be important in the
genome-scale model, but do not have other sources (structural or pharmacogenomic) of infor-
mation available, and therefore constitute examples of where our molecular modeling frame-
work is useful for filling in missing information (Table B in S1 Database).
Here, we focus the rest of this study on three distinctive proteins in erythrocyte metabolism
(Fig 3): (i) catechol-O-methyltransferase (COMT), a class I protein (according to our above
classification scheme); (ii) glucose-6-phosphate dehydrogenase (G6PD), a class I protein; (iii)
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a class II protein. For the purpose of
validation, we study the class I proteins, which have ample experimental, structural and phar-
macological data associated with their roles in metabolism. To assess the predictive value of
this workflow, we study the class II protein, a rare variant where population data was not avail-
able to understand the impact of documented sequence variants. Such an example serves as a
demonstration for how this structural systems biology framework can be used in the absence of
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experimental and pharmacological data. The targets chosen for this study and their pharmaco-
genomic importance are outlined in Table 1.
Molecular effects of sequence variation in protein-drug interactions
The next stage of our proposed workflow builds on previous methods [22,23,45,46] and lever-
ages systems modeling with molecular dynamics (MD) simulations. How SNPs/SNVs affect
structure/function relationship is a question that requires analysis beyond a comparison of
crystal structures. Here, we take advantage of using an ensemble of protein conformations,
Fig 3. a) Protein structure of COMT (WT) from PDB entry 3BWM. In orange—crystallized position of an inhibitor analog, dinitrocatechol (DNC). In blue,
cofactors needed for catalysis, S-adenosyl-methionine (SAM) and magnesium (Mg). In red, the position of the SNP (contained in PDB entry 3BWY). Zoom
in—shows the active site of the enzyme with the crystallized DNC bound. b) Protein structure of G6PD (WT) from PDB entry 2BH9. In orange—crystallized
position of the metabolite glucose-6-phosphate (G6P). In blue, the cofactor NADP+. In red, the position of the SNP. Zoom in—shows the active site of the
enzyme with G6P bound. c) Protein structure of GAPDH (WT) from PDB entry 1U8F. The orange arrow indicates the known binding site of the metabolite
glyceraldehyde-3-phosphate (G3P), which was not crystallized in the experimental structure. In blue, the cofactor NAD+. In red, the position of the SNV.
Zoom in—binding site interactions of G3P in E. coli PDB entry 1DC4.
doi:10.1371/journal.pcbi.1005039.g003
Computationally Assessing Genetic Variation in the Human Erythrocyte
PLOS Computational Biology | DOI:10.1371/journal.pcbi.1005039 July 28, 2016 7 / 24
generated from explicit solvent MD simulations, to study the effects of clinically relevant
SNVs/SNPs on drug and/or native metabolite binding (Fig 4(A)).
Catechol-O-methyltransferase (COMT). The activity of COMT in the erythrocyte, along
with the inheritance of specific polymorphisms, is often used as a biomarker for different dis-
eases, such as Parkinson’s disease or schizophrenia [47–49]. COMT plays a critical role in the
degradation of catecholamines, a class of chemicals that mostly function as neurotransmitters
in the human body [50], making it a prime target for further elucidating the effects of this SNP
on protein-drug interactions. Further, COMT plays a key role in the erythrocyte, and its rela-
tionship to pharmacogenomic implications is likely to be applicable in other systems in the
human body [51]. Of particular interest is the missense mutation, Val108Met, (i.e. Val158Met
in the membrane bound version; dbSNP ID rs4680), which may cause changes in the protein’s
response to drug inhibitors [52]. While the crystallographic structures for both wild-type and
SNP variants are available, minimal structural changes between the protein backbone of these
two proteins are observed (i.e. they align with a 0.2 Å root mean squared deviation, RMSD (Fig
E in S1 Text)) [53].
We were interested in characterizing the binding mechanism of COMT, when it is in com-
plex with either its native substrates (i.e. dopamine, epinephrine, norepinephrine) or known
inhibitors/inhibitor analogs (e.g. dinitrocatechol, tolcapone, entacapone). Flexible molecular
docking of dinitrocatechol (DNC), which is co-crystallized in both PDB structures, to the crys-
tal structures of both wild-type and SNP variants gave a RMSD of less than 1 Å (of the drug
backbone with respect to the original co-crystallized position) (Fig F in S1 Text). We find that
docking without the presence of the cofactors, (i.e., S-adenosyl methionine and a magnesium
ion), slightly increases the RMSD (by 1.5 Å) of the binding pose, as expected due to the stabiliz-
ing features and steric constraints of these cofactors [54,55]. Similar to DNC, docking of the
native metabolites to the crystallographic structures retrieved binding poses within a RMSD of
2 Å of the original bound position (comparing equivalent atoms of the co-crystallized inhibitor
DNC) (Fig G in S1 Text). The best docked poses of the two drug molecules (tolcapone and
entacapone) were initially reported about 10 Å away from the known binding site, which moti-
vated ensemble docking of both wild-type and variant proteins to understand the conforma-
tional space which was not represented in the crystal structure.
To generate an ensemble of conformations, we performed MD on both the wild-type and
SNP variant proteins, in complex with their cofactors. We find that docking DNC to an ensem-
ble of representative structures provides an increased accuracy in the final binding pose (Fig 4
(B), COMT panel), compared to docked poses to only the single crystallographic structure,
consistent with previous studies [56–60]. Ensemble docking of the catechol-like drugs and
metabolites retrieved binding poses to within 5 Å of the original crystallized position in 72% of
clustered snapshots from an MD trajectory. Furthermore, ensemble docking to wild-type
COMT has a higher frequency of reproducing the crystallized binding orientation compared to
Table 1. Signature proteins that impact erythrocyte metabolism and drug-induced phenotypes.
Gene Protein name Native metabolite Cofactors WT PDB Mutant
PDB
SNP/SNV Drugs known to
bind
Number of
exonic SNPs
COMT Catechol-O-
methyltransferase
Dopamine, epinephrine,
norepinephrine
SAM, Mg 3BWM,
3A7E
3BWY Val108Met Tolcapone,
entacapone,
113
G6PD Glucose-6-phosphate
dehydrogenase
Glucose 6-phosphate NADP+ 2BH9,
2BHL
Numerous Arg454His Phenobarbital
metabolites
206
GAPDH Glyceraldehyde-
3-phosphate
dehydrogenase
Glyceraldehyde
3-phosphate
NAD+ 1U8F Modeled Lys309Asn N/A 82
doi:10.1371/journal.pcbi.1005039.t001
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the SNP variant (Fig H in S1 Text). Following clustering of promising binding poses, we per-
formed molecular dynamics for each of the proteins in the ligand-bound states and computed
the free energy difference between the wild-type and variant proteins using MM-PBSA [61]. As
shown in Fig 4(C), we find that for the majority of cases, the mutation V108M leads to a
decreased affinity (i.e. an increase in relative binding free energy between wild-type and mutant
protein, resulting in a negative ΔΔG (ΔGWT—ΔGSNP)) to a majority of the native metabolites
and drug molecules (excluding epinephrine; see Table K in S1 Text). These findings are consis-
tent with experiments that find the SNP variant to be less stable and less active, along with vari-
ant human subjects that respond less to drug therapy [52,62,63], yet no significant
experimental differences were found with dopamine binding to the mutant [62].
Fig 4. a) Molecular modeling frameworks used for molecular simulations of metabolite and drug binding differences between wild-type and mutant (SNV/
SNP) proteins. In the first step, docking is first carried out on experimental or modeled protein structures. Frommolecular dynamics simulations, an
ensemble of structures is generated from the long-time sampling of conformations that cannot be studied from a single, static structure (e.g. crystallographic
structure). These ensemble structures provide multiple thermodynamic states of the protein that enable docking and analysis of binding free energy
estimates. The overall goal of using these molecular modeling frameworks is to quantify the relative differences in the binding affinity of metabolites and
drugs to wild-type and mutant proteins. Once these differences are computed, the ratios will be used to guide systems-level simulations. b) RMSD of
predicted ligand poses of DNC to the original crystallized position based on docking trials to only the crystal structure (blue) versus utilizing an ensemble of
structures (green). c) Differences in binding free energies fromMM-PBSA calculations in wild-type vs. mutant proteins. A negative value indicates a lower
predicted binding free energy to the wild-type protein, which corresponds to a higher binding affinity.
doi:10.1371/journal.pcbi.1005039.g004
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Glucose-6-phosphate dehydrogenase (G6PD). G6PD catalyzes the oxidation of glucose-
6-phosphate (G6P) to 6-phospho-gluconolactone (6PG) within the pentose phosphate path-
way, while maintaining the global concentration of NADPH in the erythrocyte [64], required
for protecting the cell from oxidative damage. There are more than four hundred sequence var-
iants [65], of which many are implicated in hemolytic anemia and can be heavily influenced by
drug side effects or a compromised immune system [66]. One particular missense mutation,
referred to as the “Andalus” SNP (Arg454His; dbSNP ID rs137852324), has been classified as
causing chronic nonspherocytic hemolytic anemia [67]. Structurally, the mutation occurs 21 Å
from the substrate binding site (Fig 3(B)) and is expected to impact a salt bridging interaction
with Asp286, potentially destabilizing the local structure of the protein. Notably, this arginine
residue is highly conserved throughout organisms, reinforcing its structural and functional
importance [68].
Similar to COMT, docking trials were carried out on wild-type G6PD and SNP variant
structures. The wild-type structure was modified to generate the SNP variant and structural
changes resulting from the sequence change were monitored during a 100 nanosecond trajec-
tory. As expected, the salt bridging interaction between the mutated residue and Asp286 was
eliminated (Fig I in S1 Text). We performed ensemble docking simulations of various sub-
strates to representative structures from the MD trajectory and found that, in 95% of the dock-
ing trials, G6P binds within 5 Å of the known active site of G6PD (Fig 4(B)). Although we do
not observe large-scale differences in the docking poses of G6P in wild-type versus SNP variant
proteins (Fig J in S1 Text), binding free energy calculations indicate that the SNP variant has
an increased binding affinity to the native substrate: G6P binds to the SNP variant with a
ΔΔG = 3.00 ± 0.68 kcal/mol (ΔGWT—ΔGSNP). We find that this value is consistent when com-
paring to higher accuracy methods (e.g., from thermodynamic integration (TI), we find
ΔΔG = 3.59 kcal/mol) (Fig 4(C), G6PD panel). Experiments demonstrate that this mutation
markedly increases the binding affinity of the native metabolite G6P in the variant while radi-
cally decreasing the overall turnover rate (KWTm = 52 ± 4 μM, K
SNP
m = 9.71 ± 0.67 μM, calculated
ΔΔG = 0.99 kcal/mol) [67]. Additionally, we find the SNP variant to have an increased binding
affinity to the product of the reaction, 6PG (ΔΔG = 5.81 ± 3.11 kcal/mol), and a drastically
decreased binding affinity to the cofactor NADP+ (ΔΔG = -13.057 ± 2.58 kcal/mol) at the sec-
ondary “structural” cofactor binding location [66,69]. These may also be factors that contribute
to the decreased turnover rate, such as due to a slower product release compared to wild-type
behavior or enzyme instabilities caused due to a lower population of bound NADP+.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH). GAPDH is an enzyme within
the glycolytic pathway that catalyzes the conversion of glyceraldehyde 3-phosphate (G3P) to
glycerate 1,3-bisphosphate, utilizing the cofactor NAD+. It operates as a homotetramer, and a
conserved cysteine residue (Cys149) is essential for its catalytic function [70]. Designated in
this study as a Class II pharmacogenomic enzyme, it does not have any recent documented var-
iants with phenotypic data, but from HapMap population sequencing data, a missense muta-
tion, Lys309Asn (dbSNP ID rs11549334) was identified and predicted (using PolyPhen2 and
SIFT) to be deleterious and/or disruptive (Table J in S1 Text) [71,72]. This mutant is found to
occur 19 Å away from the binding site (Fig 3(C)). As with much of the sequence of GAPDH,
this residue is conserved throughout eukaryotic organisms [73], and thus observed changes are
rare and likely marked as deleterious according to these predictive algorithms.
The Lys309Asn mutant structure was generated by modifying the sequence of the experi-
mental wild-type structure and monitoring structural changes during a 100 nanosecond trajec-
tory. In this case, ensemble docking resulted in a slight trend for more correct binding poses in
the WT ensembles when compared to the mutant (Fig 4(B), Fig K in S1 Text). Clustering of the
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docked poses was carried out based on ligand-protein interactions obtained from literature
(Table I in S1 Text) [74–76]. Computing the free energy binding difference for G3P between
wild-type GAPDH and mutant protein, we confirm that the wild-type binding affinity is stron-
ger than that of the mutant variant (ΔΔG = -3.55 ± 0.6 kcal/mol) (Fig 4(C), GAPDH panel).
The binding of the cofactor (NAD+) was found to have similar binding affinities in both forms
of the enzyme (ΔΔG = -0.5504 ± 1.8 kcal/mol). Due to the highly conserved nature of this spe-
cific residue and the suggestion of a decreased binding affinity to the native metabolite G3P,
our predictions are consistent in that it may be a cause of enzymopathy.
Systems-level effects of sequence variation related to drug responses
While understanding protein-drug interactions provides information on how sequence variation
changes protein structure and reactivity, evaluating the downstream effects of these changes
requires a systems-level perspective (Fig 5(A)). Changes in metabolic networks can be assessed
using a variety of systems methods including constraint-based and kinetic modeling techniques
[5,77–79]. To test the susceptibility of the metabolic network of the human erythrocyte to the
harmful variants detailed above, we utilized both constraint-based modeling of the iAB-RBC-283
model [8] and a recently developed in silico kinetic rate law model derived from the Mass Action
Stoichiometric Simulation (MASS) approach [80,81]. For a number of proteins, disease causing
mutations can cause systemic changes within the metabolic network or in the transport of certain
metabolites [8,82]. With regards to the erythrocyte, understanding these differences in metabolite
transport can be correlated with changes in metabolite concentrations within biofluids, which
potentially expands the use of this model as a diagnostic tool for human disease. Similar pertur-
bations can also be linked to the specific phenotypic responses of the erythrocyte, such as to drug
treatments, or the ability to respond to changes in oxidative (rate of NADPH use in order to com-
bat oxidants) or energy (rate of ATP use) load [5].
Catechol-O-methyltransferase (COMT). As COMT is not present in the core erythrocyte
kinetic model [80], we therefore turned to constraint-based modeling techniques, utilizing the
entire genome-scale model of the erythrocyte. We used the established Markov Chain Monte
Carlo-based (MCMC) sampling approach [83] to calculate distributions of all feasible flux
states for both wild-type and SNP systems. Ligand binding differences between wild-type and
SNP variant (computed from the molecular simulations) were integrated into the erythrocyte
model by altering the reaction flux bounds, which represent the rates that metabolite flow
through a reaction. We used the relative ratio of the binding affinity differences to effectively
constrain the quantitative relationship between the wild-type and mutant metabolic state as
well as the difference in behavior of the enzyme under a drug load.
Our findings suggest significant changes in the uptake of dopamine and norepinephrine,
and the secretion of their methylated counterparts (Fig 5(B)) as a result of the sequence variant.
In contrast, for epinephrine, the computed binding free energy difference in wild-type and
SNP protein was positive (i.e. it binds more strongly to the mutant), which did not influence
network analysis of the uptake or secretion of its associated metabolites. Furthermore, the
mutant COMT decreases the effectiveness of the drugs entacapone and tolcapone, which is
again reflected by an increase in the secretion of the methylated metabolites when compared to
the wild-type cell inhibited by these drugs. These findings are consistent with previous studies
related to entacapone, which report decreased efficacy of entacapone in individuals with the
SNP (Met108) [52], though it may be dependent on different human-specific characteristics
[84] and tolcapone, which has a reported increased efficacy in individuals with the wild-type
(Val108) [85]. These findings oppose the previous claim that the genotype did not contribute
to the clinical response [86].
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Fig 5. a) Systemsmodeling framework used in this study. Inputs used for constraint-based and kinetic
modeling are derived frommolecular modeling calculations and experimental data when available. In order to
understand how small-scale changes from enzyme variants affect the entire system, we look at the internal
system changes (in reaction flux and metabolite concentration), differences in metabolite import & export,
and how the cell handles an increase in oxidative or energy loads. Oxidative load is defined as the conversion
of NADPH to NADP+, whose rate of reaction is increased under states of oxidative stress. Energy load is
defined as the use of ATP. For all panels, the change in metabolic flux is colored by a difference from the wild-
type flux state, red being a decreased flux in the mutant state and blue being an increased flux. b) Constraint-
based modeling for the mutant COMT enzyme. The SNP is predicted to decrease the binding affinity of the
enzyme in norepinephrine and dopamine metabolism. Increasing the Km (predicted) of COMT for the
respective reactions leads to decreased flux and as a result decreased export of their methylated
counterparts. Inhibitors tolcapone (TCW) and entacapone (ENT) are also predicted to have a lowered binding
affinity to COMT, leading to similar effects. c) Kinetic modeling for the mutant G6PD enzyme. Decreases of
the Km (predicted and experimental) and of the Kcat (experimental) lead to major systemic changes of the
pentose phosphate pathway and glycolysis. The ratio of NADPH to NADP+ greatly decreases and
subsequently the oxidative load able to be handled also decreases. d) Kinetic modeling for the mutant
GAPDH enzyme. The cell is unable to handle the predicted increase in Km (predicted) and results in an
infeasible state of the model, corresponding to cell lysis.
doi:10.1371/journal.pcbi.1005039.g005
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Glucose-6-phosphate dehydrogenase (G6PD). In patients with G6PD deficiency, the
most common symptom is hemolytic anemia resulting from the erythrocyte’s loss of ability to
respond to oxidative stress. This ability can be measured by simulating an increase in the oxida-
tive load within a kinetic modeling framework. The predicted increase in binding affinity of
G6P to the mutant enzyme corresponds to the experimentally calculated binding affinity
reported in [67]. If we assume the same catalytic rate (Kcat) of the reaction carried out by this
enzyme, the cell’s ability to respond to an oxidative load does not decline. Though the ratio of
NADPH to NADP+ increases, it does not lead to a significant increase in the oxidative load tol-
erated when compared to the baseline, wild-type model. Integrating the experimentally mea-
sured Kcat from [67], however, drastically reduces the ratio of NADPH to NADP
+ and
subsequently lowers the maximum tolerable oxidative load of the cell under stress conditions
(Fig 5(C)). Incorporating these kinetic parameters within the erythrocyte model, we find spe-
cific systemic effects that correspond to the classification of this SNP as a “severe deficiency
with intermittent hemolysis” by the WHO [87]. This behavior is also observed in constraint-
based modeling after decreasing the flux through the corresponding reaction and induces sig-
nificant changes (defined as<40% the original, wild-type flux span, see Methods) in the gluta-
thione reductase pathway, which utilizes NADPH to combat oxidative stress.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH). GAPDH deficiencies in humans
are rare, and mostly cause mild hemolytic anemia [88]. By integrating the relative change in
Km of the mutant, based on binding free energy computations, into the erythrocyte kinetic
model, we observed that this change led to lethality (Fig 5(D)). Smaller relative changes in the
Km or Kcat (compared to wild-type) were not lethal and did not impact the ability of the eryth-
rocyte to respond to an increase of oxidative or energy load, suggesting that only a small degree
of change in protein structure and reactivity may be tolerated. This finding is consistent with
studies in mice where those with lower activity mutants or those heterozygous for a lethal
mutant rarely showed symptoms, while those homozygous for a mutant encountered mortality
at the development stage [89]. The human subject with this annotated variant (within the Hap-
Map dataset) was noted as having a heterozygous form of this specific mutant, which would
explain the non-lethality observed. It is important to note that GAPDH is involved in several
non-metabolic processes [90], and while variation of the enzyme sequence may be tolerated to
a certain extent, these additional processes may be impacted due to the causal effect of this
mutation.
Conclusion
Here, we propose a framework for mapping protein structural information to genome-scale
models of human erythrocyte metabolism for the characterization SNP-drug associations.
Three case studies presented in this contribution point to the complexity of pharmacogenomic
associations and being able to conduct integrated in silico simulations that extend from the
molecular scale to the systems level. Using parameters from molecular simulations to guide
genome-scale modeling, we are able to study how changes in protein structure and binding
affinity influence the phenotypic states of an entire metabolic network. We find that the union
of genome-scale modeling and molecular, physics-based methods, presents, to the best of our
knowledge, the first workflow capable of systematically integrating data from pharmacogeno-
mics research, in conjunction with 3D high resolution protein structural information, to model
changes on both the pathway (i.e. metabolic network) and molecular (i.e. protein) scales. The
information gained through molecular modeling simulations can be utilized to supply parame-
ters to both kinetic models and constraint-based modeling approaches and has been found to
be amenable to the study of other enzymopathies [5,91]. Our findings indicate that there is
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consistency between experimental and computational trends in substrate and drug compound
binding in wild-type versus mutant proteins.
Currently, most systems biology approaches lack the ability to utilize insights from struc-
ture-based analyses related to metabolite and/or drug binding. Fortunately, atomistic molecu-
lar simulations have evolved to become powerful tools for the characterization of binding
mechanisms and as such constitute valuable assets for systems modeling. Extending analysis
beyond crystallographic structures through the use of ensemble confirmations substantially
enhances the predictive scope of docking methods by identifying alternative binding modes for
a drug molecule [56–60]. Ensembles of the thermodynamically accessible states of a protein,
generated from molecular dynamics, allows for the mechanistic characterization of how
sequence and structural variation may influence metabolite or drug binding [92].
The scalability of this workflow is mainly limited (i) to the documentation and experimental
analysis of exonic SNVs/SNPs, and (ii) by the execution of molecular dynamics simulations,
which takes a significant manual effort and requires high performance computing resources.
For the second point, certain efforts have already shown that high-throughput simulations
using classical MD can be performed on large numbers of proteins [93,94]. However, perform-
ing high accuracy computations on a systems scale is currently intractable, due to the intense
computational and time requirements of quantum-based simulations or free energy calcula-
tions. Therefore, a trade-off between accuracy and cost must be considered (see Fig B in S1
Text and recent reviews on the subject [95–97]). In light of these limitations, we find that the
additional information gained from protein structure greatly contribute to our understanding
of causal mutations and can assist in selecting protein targets for more detailed molecular stud-
ies. Thus, when combined with other developing frameworks [4] and experiments [98], the
contributed workflow provides a first step in the translation of Big Data in the pharmaceutical
industry to practical therapeutic applications and is expected to have a positive transformative
impact on the fields of systems medicine, population studies and drug discovery efforts.
Methods
GEM-PRO construction
The techniques used here are a consolidation of 4 previous methods to add protein structural
information to genome-scale models [22,23,99,100], and described in detail in [28]. To do so,
the SBML model of the erythrocyte genome-scale model was first obtained from the BiGG
Models website (http://bigg.ucsd.edu/models/iAB_RBC_283) [101], and all gene IDs were
mapped to their corresponding amino acid sequences (UniProt and RefSeq entries). This
model differed from the construction of previous GEM-PROs due to the appearance of protein
isoforms, and required additional manual mapping to ensure correctness. Gene isoforms led to
inconsistencies between database entries and additional difficulty linking to available homol-
ogy models (discussed in the section “Homology Modeling”). Additional QC/QA steps were
taken in order to ensure the correct sequence was being retrieved, as described below.
Mapping to UniProt accession numbers. For a given gene in iAB-RBC-283, there are a
number of associated isoforms, annotated as the gene name and a isoform number, separated by
a decimal (eg. "Aldoa.1"). We take the gene name, which is taken from the corresponding gene in
Recon 2, obtain the Entrez gene ID [102], and directly map this to its corresponding UniProt
accession code (UAC). Then, we directly map isoform numbers to available isoforms in the UAC
entry (Fig A in S1 Text, top panel). These are annotated with reviewed isoform-specific
sequences, allowing us to filter for the correct experimental PDB structure in later stages.
Mapping to RefSeq and Ensembl identifiers. In some cases, the number of isoform
sequences annotated in iAB-RBC-283 does not match the number of isoforms available in
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UniProt. For these, we generated a separate mapping pipeline to the RefSeq and Ensembl data-
bases [103]. The Bioservices Python package [104] and Ensembl Biomart tables [105] were
used in order to first map the gene IDs without their isoform identifier to their corresponding
entries, and then back to isoform IDs according to the transcript name as listed in Ensembl
(see Fig A in S1 Text, bottom panel). The information here was also utilized in order to cross-
reference what was successfully mapped with the UniProt mapping service. Once the correct
isoform entry was found, available PDB mappings were found using the entry ID (RefSeq or
Ensembl Protein), or by sequence alignment to the PDB. We note that the difficulty in map-
ping isoforms and inconsistencies between databases points to a larger need of consistency and
standardization for this biological property.
Homology modeling. We have filled in the gaps where there are no experimental struc-
tures by querying previously generated databases of I-TASSER homology models for H. sapiens
[43], and manually generating homology models for genes that were not part of these databases
[44]. The I-TASSER Suite version 4.4 was utilized for the construction of missing structures,
and provides an especially useful method in modeling splice isoforms, which are specialized in
the erythrocyte [106]. In the final GEM-PRO data frame, we note where available homology
models have been mapped to their respective genes. We also include additional information in
the data frame that explains the type of computational prediction method used to model the
protein structure (e.g. template-based versus ab initio), the corresponding URL (for download-
ing the homology file from the source), the label (i.e. the identifier of the model given by the
homology model database), and information related to the confidence of the homology model
(e.g. C-score), the native (homologous) template used for the model, etc. All columns added to
the master data frame from this stage are preceded by a ‘i’ for I-TASSER. It is important to
note that certain PDB structures with unresolved residues or gaps in the structure can also be
homology modeled to enhance the structural coverage of the amino acid sequence. Quality
scores for each model are included as PSQS and PROCHECK scores [107,108].
QC/QA procedure. For the purpose of molecular modeling, it is important to select high-
quality starting structures when conducting docking or molecular dynamics simulations. On a
genome-scale, an automatic ranking system becomes a requirement if there are multiple structures
or homology models that represent one gene. The main objective of this section is to discuss the
quality assessment and quality control of the data that has been thus far mapped to the metabolic
network reconstruction. In previous versions of GEM-PROs, experimental structures were addi-
tionally classified and ranked according to whether a protein was bound to a native metabolite or
ligand, in order to ensure proper binding predictions. While the updated version of the GEM-PRO
modeling framework does not include the bound state of a protein as a target characteristic in the
quality control pipeline, this data is accessible in the knowledge base. Instead, we are mainly inter-
ested in quantifying the general quality attributes of the experimental structure of the protein.
An ideal starting platform for higher-level modeling methods are experimental protein
structures without missing residues (especially at the interior of the protein) and 100%
sequence identity compared to wild-type. To determine which experimental structures
required further modeling or modification, we devised a scoring metric that ranks each PDB
based on 1) the coverage of the wild-type amino acid sequence, 2) the resolution, and 3) the
similarity of secondary structural features between the PDB structure and its corresponding
homology model. The final outcome of the quality assessment is the classification of experi-
mental structures into three groups: (i) high quality structures requiring no modification; (ii)
high quality structures requiring minimal (site-directed) modification and (iii) low quality
structures requiring homology modeling. For more information on the ranking scheme, please
see S1 Text and [28]. All protein structure files following ranking and quality control are
included within S3 Database.
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Genetic variation, drug-target interactions, and essential genes
Previous work was done to map data from the Online Mendelian Inheritance in Man (OMIM)
database in order to find disease causing mutations that could map to erythrocyte proteins [8].
We also collected all known SNPs from dbSNP, and filtered them down to variations in exons
that could be studied utilizing protein structure information. Information was additionally
cross-referenced with UniProt variant annotations [109].
There are a number of drug target databases that were queried for this study. DrugBank was
used in a previous study to gather drug targets based on sequence [8]. In order to be as compre-
hensive as possible, we also obtained data from ChEMBL [110] and MATADOR [42], with
MATADOR providing annotations for indirect interactions. With this, we were able to verify
targets that appeared in all 3 databases. Drug adverse effects due to variation were mainly gath-
ered from the PharmGKB, a pharmacogenomics database with information from clinical stud-
ies, research articles, and individual cases [111]. The PharmGKB further annotates for the
significance of an association, as well as details of the clinical trial or GWAS study carried out.
Finally, the DrugBank contains a simple list of SNP-drug associations in their SNP-ADR and
SNP-FX sub-databases [41], which was cross-referenced with all information found in the
PharmGKB.
As a final source of parameters for validation of our model, experimentally determined
kinetic values for binding of a drug or inhibitor to a target (wild-type as well as mutant) were
obtained from BRENDA and the BindingDB [112,113]. As expected, information for this step
was much sparser than the previous information, which indicates the need for experimental
assays if we are to validate the predictions made from this model. For the targets in this study,
we also manually searched for additional information from published biochemical studies.
Finally, for the selection of interesting targets to study with molecular and systems modeling
techniques, we also wanted to understand the essentiality of each gene within the erythrocyte
model. Gene knockouts were performed for each gene contained within iAB-RBC-283, as per
[8]. A gene was marked as interesting to study within the context of the erythrocyte if there
were significant changes within the reaction fluxes of metabolite import and export through
the membrane using flux variability analysis (FVA) simulations [114]. In order to detect these
significant differences, all reaction fluxes were compared to the normal “wild-type” state of the
cell. Specifically, similar procedures to Shlomi et al. and Bordbar et al. were followed [8,82].
Changes in exchange fluxes were categorized into i) activation/inactivation, ii) shift to a fixed
direction, iii) a change in magnitude of flux, or iv) no change (refer to [8], Fig 5). For changes
in magnitude of flux, if the new flux span (defined as maximum flux—minimum flux) was less
than 40% of the original flux span, it was considered to be a significant change.
Molecular modeling and docking
Experimental PDB structures or homology models representing the genes of interest in this
study were taken from the GEM-PRO data frame following ranking and QC/QA. Mutant
forms of the enzymes were either taken directly from the PDB, if available, or modeled by
point mutations of the structure. Next, the general approach for each target was to first under-
stand the binding position and energetics of either the native metabolite or a drug of interest to
a wild-type protein structure and its corresponding mutant. Flexible docking simulations using
DOCK6 were carried out with default parameters and binding sites defined when known
[115]. Furthermore, simulations were conducted with and without cofactors, to account for
competitive binding drugs or cases where the order of substrate binding was not known. To
compare flexible docking results to ensemble docking, simulations were repeated under differ-
ent random seeds for a total of 500 docking runs.
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Molecular dynamics simulations and ensemble docking
Molecular dynamics simulations were run utilizing the PMEMDmodule of the AMBER14
toolkit [116]. Initial parameterization of ligands and cofactors were carried out utilizing the
Gaussian 09 software [117] or obtained from previously published data sets (see S1 Text for
protein-specific methods and S2 Database for parameter sets). For generating topologies as
input to AMBER, 99SB force field charges and atom types were then used and then solvated in
a periodically repeated TIP3P 12 Å water box with counterions being added as needed (Na+ or
Cl-). Minimization was carried out under constant volume conditions at while being heated to
300 K. Structures were then equilibrated under constant temperature and pressure conditions
with restraints being released. Finally, the structures were run in production phase of 75 ns or
more under a Langevin thermostat and Particle Mesh Ewald (PME) cutoff of 12 Å.
At least 4 separate MD simulations (representing WT and SNP structures in cofactor
unbound and bound states, more for additional cofactor bound states) were carried out on
each enzyme (see Tables D-F in S1 Text for all simulation information). Every 100 frames from
these trajectories were utilized as input for ensemble docking of the substrate of interest.
All docked positions were clustered into 5 representative poses based on the distances from
known binding residues. Specifically, distances from 3 known binding or interacting residues
to the atoms of the drug or metabolite were calculated for each extracted frame, and k-means
clustering of the Euclidean distance separated these frames into 5 distinct binding modes for
use in further simulation. These docked positions were subject to additional MD production
runs of 10 ns each, in order to examine the stability of the bound position and if they would
converge into one distinct pose. We conducted free energy calculations for each of the ligands
in the cofactor bound state of the WT and SNP enzymes. MM-PBSA calculations were carried
out to predict the difference in free energies of binding (ΔΔG). The binding energies of all 5
representative conformations were averaged per ligand, and the resulting value indicates if the
ligand is more favorable to bind to WT (negative ΔΔG) or SNP (positive ΔΔG) structures.
Binding energy calculations
MM-GBSA/MM-PBSA calculations utilizing the MMPBSA.py script available in the
AMBER14 toolkit were carried out on the 10 ns simulated receptor-ligand complexes [61]. The
first nanosecond of simulations was discarded before running calculations to account for initial
stabilization of the docked ligand. Thermodynamic integration (TI) calculations were calcu-
lated utilizing the Simulated Annealing with NMR-derived Energy Restraints (SANDER) mod-
ule within AMBER14 [118]. The dual topology paradigm was utilized with a three step
alchemical transformation, with state 0 representing a wild-type enzyme and state 1 the mutant
form. Step 1 carried out the decharging of the WT utilizing 10 λ points and simulations of 1 ns
each. Step 2 transformed the residue atoms of the WT to the SNP again utilizing 10 λ points
and simulations of 1 ns each. Step 3 carried out the recharging of the mutant residue atoms
with the same number of λ points and simulation time. This was run for both ligand bound
and unbound states. Finally, the change in potential energy of the system with ligand bound
was calculated by integration over the λ points and subtracted from the ligand unbound state.
For full information on docking, MD, MM-PBSA, and TI parameters, please refer to the sec-
tion entitled “Molecular modeling simulations” in S1 Text.
Systems modeling
The constraint-based modeling approach was carried out for all enzymes in this study by simu-
lating a normal (wild-type) and perturbed (mutant) erythrocyte condition utilizing FVA fol-
lowed by a Markov chain Monte Carlo (MCMC) based sampling approach [83,91,119].
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Previous simulations for identifying biomarkers have simulated perturbed states by setting the
upper and lower bounds of flux through affected enzymes of the cell to 0, effectively mirroring
a full gene inhibition, and then analyzing the exchange conditions [8,82]. For the purposes of
this study, we are now able to understand the relative differences in native metabolite catalysis
utilizing the ratio of differences in the binding affinity between wild-type and mutant forms of
the enzymes. This ratio was then converted into a ratio of flux in wild-type to mutant enzymes,
assuming equal concentration of substrate and enzyme (see Equation S3). From this, the deter-
mined normal wild-type minimum and maximum fluxes through the corresponding reaction
were adjusted to a perturbed mutant state, and both FVA and MCMC simulations were then
run with the goal of analyzing 1) the flux differences through the exchange reactions (import/
export of metabolites) of the erythrocyte (as described above in the section “Genetic variation,
drug-target interactions, and essential genes”) and 2) significant flux shifts within the internal
network. In this way, hypotheses for the altered phenotypic state of the erythrocyte and its
impact on the body could be deduced based on the differences of uptake or secretion of metab-
olites or large-scale internal network changes. For MCMC simulations, significant shifts in the
distribution of fluxes were considered (p-value< 0.05). Additional information on MCMC
sampling is included in the section entitled “Systems modeling” in S1 Text.
With the kinetic rate law model, we are able to directly integrate the predicted Km and
experimental Kcat values as well as simulate the cell under oxidative or energy load conditions.
This detailed model was utilized for the simulations of normal and perturbed G6PD and
GAPDH enzymes. Simulation of COMT within the kinetic model was not available due to the
current model being limited to core metabolic enzymes. We utilize the model to also under-
stand the erythrocyte’s capability to withstand oxidative stress or increased energy needs and
compare wild-type to mutant states. Oxidative stress is simulated as an increase in the rate of
NADPH usage, to mirror the fact that a cell under stress requires NADPH to neutralize reac-
tive oxygen species. Energy load is simulated as an increase in the rate of ATP usage. The nor-
mal, wild-type cell was first simulated and the maximum oxidative and energy loads were
determined for comparison to the mutant state. Integration of the predicted Km without any
change in Kcat was then simulated for the mutant state, to understand if only changes in bind-
ing affinity led to a change in maximum tolerable oxidative or energetic load. Finally, changes
from predicted Km, experimental Km, and experimental Kcat were fully integrated to investigate
the model’s accuracy to the known phenotype.
Supporting Information
S1 Text. Expanded methods and results text and figures detailing GEM-PRO construction,
molecular modeling simulations, and systems modeling.
(PDF)
S1 Database. GEM-PRO of the human erythrocyte and related pharmacogenomics files.
Table A: GEM-PRO for iAB-RBC-283 (denoted as iNM-RBC-283-GP in the main text).
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